Inhibiting angiogenesis in retinoblastoma

Ophthalmic Research

Volumn 39, Issue 4, 2007, Pages 188-190

  Apte, Rajendra S ^a   Harbour, J William ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANECORTAVE; BEVACIZUMAB; BEVASIRANIB; PEGAPTANIB; RANIBIZUMAB; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN E; VASCULOTROPIN INHIBITOR; VITAMIN D;

ANGIOGENESIS; CELL VIABILITY; CHOROID DISEASE; CLINICAL TRIAL; DIABETIC RETINOPATHY; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG TARGETING; EDITORIAL; HISTOPATHOLOGY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA MACULA AGE RELATED DEGENERATION; RETINOBLASTOMA; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CHOROIDAL NEOVASCULARIZATION; DIABETIC RETINOPATHY; HUMANS; MACULAR DEGENERATION; RETINAL NEOPLASMS; RETINOBLASTOMA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34547748467     PISSN: 00303747     EISSN: None     Source Type: Journal    
DOI: 10.1159/000103578     Document Type: Editorial

References (19)

1. Harbour JW: Retinoblastoma: treatment; in Char DH (ed): Tumors of the Eye and Orbit. Philadelphia, B.C. Decker, 2001, pp 66-278.
2. Eng C, Li FP, Abramson DH, Ellsworth RM, Wong FL, Goldman MB, Seddon J, Tarbell N, Boice JJ: Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst 1993;85:1121-1128.
3. Murphree AL, Villablanca JG, Deegan WF 3rd, Sato JK, Malogolowkin M, Fisher A, Parker R, Reed E, Gomer CJ: Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol 1996;114:1348-1356.
4. Bornfeld N, Schuler A, Bechrakis N, Henze G, Havers W: Preliminary results of primary chemotherapy in retinoblastoma. Klin Padiatr 1997;209:216-221.
5. Kvanta A, Steen B, Seregard S: Expression of vascular endothelial growth factor (VEGF) in retinoblastoma but not in posterior uveal melanoma. Exp Eye Res 1996;63:511-518. 6 Marback EF, Arias VE, Paranhos A Jr, Soares FA, Murphree AL, Erwenne CM: Tumour angiogenesis as a prognostic factor for disease dissemination in retinoblastoma. Br J Ophthalmol 2003;87:1224-1228.
6. Shokravi MT, Marcus DM, Alroy J, Egan K, Saornil MA, Albert DM: Vitamin D inhibits angiogenesis in transgenic murine retinoblastoma. Invest Ophthalmol Vis Sci 1995;36:83-87.
7. AG mice. Invest Ophthalmol Vis Sci 2006;47:1264-1268.
8. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-1309.
9. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 2003;9:669-676.
10. Bhisitkul RB: Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol 2006;90:1542-1547.
11. Cunningham ET Jr, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'Amico DJ, Goldbaum M, Guyer DR, Katz B, Patel M, Schwartz SD: A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005;112:1747-1757.
12. Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM: A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 2006;113:1706-1712.
13. Russell SR, Hudson HL, Jerdan JA: Anecortave acetate for the treatment of exudative age-related macular degeneration - a review of clinical outcomes. Surv Ophthalmol 2007;52(suppl 1):S79-S90.
14. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR: Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816.
15. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
16. Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW Jr, Gonzalez S, Feuer WJ, Lin RC, Lalwani GA, Nguyen JK, Kumar G: Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495-511.
17. Karagiannis TC, El-Osta A: RNA interference and potential therapeutic applications of short interfering RNAs. Cancer Gene Ther 2005;12:787-795.
18. Shen J, Samul R, Silva RL, Akiyama H, Liu H, Saishin Y, Hackett SF, Zinnen S, Kossen K, Fosnaugh K, Vargeese C, Gomez A, Bouhana K, Aitchison R, Pavco P, Campochiaro PA: Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther 2006;13:225-234.
19. Jia RB, Zhang P, Zhou YX, Song X, Liu HY, Wang LZ, Luo M, Lu J, Ge SF, Fan XQ: VEGF-targeted RNA interference suppresses angiogenesis and tumor growth of retinoblastoma. Ophtalmic Res 2007;39:108-115.